Benjamin Edwards Inc. Has $911,000 Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Benjamin Edwards Inc. increased its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 680.5% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 1,717 shares of the medical research company's stock after buying an additional 1,497 shares during the period. Benjamin Edwards Inc.'s holdings in Thermo Fisher Scientific were worth $911,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Raleigh Capital Management Inc. boosted its stake in Thermo Fisher Scientific by 49.1% in the 3rd quarter. Raleigh Capital Management Inc. now owns 82 shares of the medical research company's stock valued at $41,000 after purchasing an additional 27 shares during the period. Cedar Mountain Advisors LLC increased its position in Thermo Fisher Scientific by 107.0% during the fourth quarter. Cedar Mountain Advisors LLC now owns 89 shares of the medical research company's stock worth $47,000 after acquiring an additional 46 shares during the period. Financial Connections Group Inc. acquired a new stake in Thermo Fisher Scientific in the 4th quarter worth about $53,000. Operose Advisors LLC grew its position in shares of Thermo Fisher Scientific by 250.0% during the 3rd quarter. Operose Advisors LLC now owns 105 shares of the medical research company's stock worth $53,000 after purchasing an additional 75 shares in the last quarter. Finally, Valley National Advisers Inc. increased its holdings in shares of Thermo Fisher Scientific by 40.5% during the third quarter. Valley National Advisers Inc. now owns 111 shares of the medical research company's stock worth $56,000 after purchasing an additional 32 shares during the period. 89.23% of the stock is owned by institutional investors.

Thermo Fisher Scientific Trading Up 0.1 %

NYSE TMO traded up $0.70 during trading hours on Friday, reaching $571.95. The company's stock had a trading volume of 1,749,669 shares, compared to its average volume of 1,549,649. Thermo Fisher Scientific Inc. has a 52 week low of $415.60 and a 52 week high of $603.82. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.70 and a quick ratio of 1.33. The stock has a market cap of $218.32 billion, a P/E ratio of 36.71, a P/E/G ratio of 2.38 and a beta of 0.80. The firm has a fifty day simple moving average of $575.24 and a 200-day simple moving average of $532.25.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 EPS for the quarter, topping analysts' consensus estimates of $4.70 by $0.41. The company had revenue of $10.35 billion for the quarter, compared to analyst estimates of $10.14 billion. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. Equities analysts forecast that Thermo Fisher Scientific Inc. will post 21.64 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, April 15th. Investors of record on Friday, March 15th were paid a $0.39 dividend. This is a positive change from Thermo Fisher Scientific's previous quarterly dividend of $0.35. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.27%. The ex-dividend date was Thursday, March 14th. Thermo Fisher Scientific's payout ratio is currently 10.01%.

Insider Activity at Thermo Fisher Scientific

In other news, SVP Michael A. Boxer sold 14,566 shares of the stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the completion of the sale, the senior vice president now directly owns 12,901 shares in the company, valued at $7,250,362. The transaction was disclosed in a filing with the SEC, which is available at this link. In related news, Director Debora L. Spar sold 164 shares of the firm's stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $546.97, for a total transaction of $89,703.08. Following the completion of the sale, the director now owns 1,207 shares of the company's stock, valued at $660,192.79. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Michael A. Boxer sold 14,566 shares of the business's stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the transaction, the senior vice president now directly owns 12,901 shares in the company, valued at $7,250,362. The disclosure for this sale can be found here. Insiders have sold 62,277 shares of company stock worth $35,373,364 over the last ninety days. Insiders own 0.34% of the company's stock.

Wall Street Analysts Forecast Growth

TMO has been the topic of a number of analyst reports. Barclays increased their price target on Thermo Fisher Scientific from $590.00 to $615.00 and gave the stock an "equal weight" rating in a research report on Thursday, April 25th. Royal Bank of Canada boosted their price target on Thermo Fisher Scientific from $592.00 to $642.00 and gave the company an "outperform" rating in a research note on Thursday, February 1st. JPMorgan Chase & Co. increased their price objective on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an "overweight" rating in a research note on Thursday, April 25th. The Goldman Sachs Group upped their price target on shares of Thermo Fisher Scientific from $550.00 to $640.00 and gave the stock a "buy" rating in a report on Wednesday, April 10th. Finally, HSBC lifted their price objective on shares of Thermo Fisher Scientific from $660.00 to $670.00 and gave the company a "buy" rating in a research note on Tuesday. Five research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $607.35.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.